



GSK

4,689,680 followers


10mo • 




Recurring chronic obstructive pulmonary disease (COPD) exacerbations can accelerate disease progression and further increase the risk of hospitalisation. At GSK we're committed to understanding how to slow COPD progression and redefining the future of respiratory medicine.

Learn more: <https://gsk.to/4jQTB6G>

Did you know...



**... 40% of people
with COPD continue to
experience exacerbations
despite maximum inhaled
triple therapy?**



**...a single moderate/
severe COPD exacerbation
can increase the risk of
future exacerbations or
admission to hospital?**

NP-GBL-CPU-SMP-240003
Date of preparation: October 2024



... that COPD
is the **3rd** leading
cause of death
worldwide?